- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06945718
Résultats cliniques du traceur vert indocyanine en utilisant dans une gastrectomie laparoscopique avec lymphadénectomie étendue au-delà du D2 pour le cancer gastrique localement avancé (FUGES-30)
Essais contrôlés randomisés prospectifs sur les résultats cliniques du traceur vert indocyanine en utilisant dans une gastrectomie laparoscopique avec une dissection ganglionnaire extrarégionale D2 pour un cancer gastrique localement avancé (FUGES-30)
Taking patients with locally advanced gastric adenocarcinoma (cT2-4a, N-/+, M0) as the research subjects, to evaluate whether the clinical efficacy of laparoscopic beyond D2 regional lymph node dissection for gastric cancer with indocyanine green tracer is better or not.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Mi Lin, phD
- Numéro de téléphone: 13459152658
- E-mail: silihuala@qq.com
Sauvegarde des contacts de l'étude
- Nom: Hua-Long Zheng, phD
- Numéro de téléphone: 18359190587
- E-mail: 291167038@qq.com
Lieux d'étude
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350001
- Recrutement
- Fujian Medical University Union Hospital
-
Contact:
- Changming Huang, M.D., Ph.D.
- Numéro de téléphone: +86-133-6591-0253
- E-mail: hcmlr2002@163.com
-
Chercheur principal:
- Changming Huang, M.D., Ph.D.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition
La description
Inclusion Criteria:
Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale ASA (American Society of Anesthesiology) class I to III Written informed consent
Exclusion Criteria:
Women during pregnancy or breast-feeding Severe mental disorder History of previous upper abdominal surgery (except for laparoscopic cholecystectomy) History of previous gastric surgery (including ESD/EMR for gastric cancer) Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging including enlarged or bulky lymph nodes in D3 region.
Other malignant disease within the past 5 years History of unstable angina or myocardial infarction within past six months History of cerebrovascular accident within past six months History of continuous systematic administration of corticosteroids within one month Requirement for simultaneous surgery for other disease Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer FEV1 (forced expiratory volume in one second)<50% of predicted values Diffuse invasive gastric cancer Tumors preoperatively confirmed to involve the squamocolumnar junction or duodenum History of an iodine allergy Patients who declined laparoscopic surgery
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
laparoscopic gastrectomy with beyond D2 regional fluorescent lymph node dissection with ICG group
ICG with D2+ group |
dissect the lymph nodes outside the extent of D2 LN region. |
|
laparoscopic gastrectomy with D2 regional lymph node dissection with ICG group
ICG with D2 group |
dissect the lymph nodes outside the extent of D2 LN region. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
3-year disease free survival rate
Délai: 3 years
|
Disease-free survival is calculated from the day of surgery to the day of recurrence or death |
3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total number of retrieved lymph nodes
Délai: 30 days
|
Total number of retrieved lymph nodes |
30 days
|
|
Noncompliance rate of lymph node dissection
Délai: 30 days
|
The LN dissection rate was determined by the number of patients in whom a LN station was harvested divided by the total number of patients who required retrieval at the corresponding LN station. Within the scope of D2 dissection, LN noncompliance was defined as the absence of LNs that should have been resected from > 1 LN station. |
30 days
|
|
Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A
Délai: 30 days
|
Relationship between the number of fluorescent lymph nodes in group A and total number of lymph nodes in group A |
30 days
|
|
Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)
Délai: 30 days
|
The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (True positive rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)
Délai: 30 days
|
The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate). |
30 days
|
|
Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)
Délai: 30 days
|
The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group A (True negative rate). |
30 days
|
|
Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)
Délai: 30 days
|
The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group A (false negative rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B
Délai: 30 days
|
Relationship between the number of fluorescent lymph nodes in group B and total number of lymph nodes in group B |
30 days
|
|
Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)
Délai: 30 days
|
The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group B (True positive rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in Group B and negative lymph nodes in Group B (false positive rate)
Délai: 30 days
|
The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate). |
30 days
|
|
Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)
Délai: 30 days
|
The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group B (True negative rate). |
30 days
|
|
Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)
Délai: 30 days
|
The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group B (false negative rate). |
30 days
|
|
Number of metastatic lymph nodes
Délai: 30 days
|
Number of metastatic lymph nodes |
30 days
|
|
Metastasis rate of lymph nodes
Délai: 30 days
|
Metastasis rate of lymph nodes |
30 days
|
|
Postoperative complications
Délai: 30 days
|
Postoperative complications were evaluated within 30 days following surgery. These postoperative complications include gastrointestinal-related complications, incision-related complications, respiratory complications, cardiovascular and cerebrovascular complications, urinary system complications, infection complications, embolism complications, and other complications. The grading of postoperative complications adopts the Clavien-Dindo classification. |
30 days
|
|
Mortality rates
Délai: 30 days
|
Patient died during hospitalization. |
30 days
|
|
3-year overall survival rate
Délai: 3 years
|
3-year overall survival rate |
3 years
|
|
3-year recurrence pattern
Délai: 3 years
|
3-year recurrence pattern |
3 years
|
|
Postoperative recovery course
Délai: 30 days
|
Time to first flatus after surgery, time to first ambulation after surgery, time to first liquid diet after surgery, time to first semi-liquid diet after surgery, length of hospital stay after surgery. |
30 days
|
|
The incidence of intraoperative complications
Délai: 30 days
|
Intraoperative complications were defined as bleeding due to named vessel injury, injury to visceral organs, mechanical factor-related problems, cardiopulmonary dysfunction due to hypercapnia, and other complications |
30 days
|
|
Inflammatory and immune response
Délai: 7 days
|
the values of hemoglobin, prealbumin, albumin, C-reactive protein, and white blood cell count from peripheral blood before the operation and on postoperative day 1, 3, 5 are recorded. |
7 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Chang-Ming Huang, Prof., Fujian Medical University Union Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- FUGES-30
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .